Shots:
- Eli Lilly has entered into a definitive agreement to acquire Merida Biosciences incl. its antibody-engineering platform & programs, strengthening Lilly’s immunology capabilities
- As per the deal, Eli Lilly will acquire Merida Biosciences for $2.875B in cash, incl. an upfront payment, & contingent milestone payments; closing is expected in the Q4’26
- Merida’s lead program, MER511, is in P-I for Graves’ disease & thyroid eye disease, while MER769 is a preclinical program targeting food allergy, asthma & chronic spontaneous urticaria. Its platform aims to durably remove disease-causing antibodies while preserving normal immune function
Ref: PRnewswire | Image: Merida Biosciences | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
